RT Journal Article
SR Electronic
T1 PS-017 Using treatment protocols in the verification of oral anticancer drug prescriptions
JF European Journal of Hospital Pharmacy
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP A142
OP A143
DO 10.1136/ejhpharm-2015-000639.343
VO 22
IS Suppl 1
A1 F O’Shaughnessy
A1 L Hammond
A1 AM De Frein
A1 J O’Shea
A1 C Keane
YR 2015
UL http://ejhp.bmj.com/content/22/Suppl_1/A142.2.abstract
AB Background A lack of information at the time of dispensing has been identified as a barrier to the safe provision of Oral Anticancer Medicines (OAMs) by pharmacists. Access to cancer treatment protocols at the time of pharmacist dispensing is advocated by numerous professional bodies to ensure the safe supply of OAMs.1,2 Purpose To compare the number of OAM prescriptions that could be verified and safely dispensed with and without access to the treatment protocol, and to assess the use of these protocols by pharmacists.Material and methods One hundred OAM prescriptions were retrospectively reviewed to assess OAM verification with and without the treatment protocol. An electronic questionnaire was also distributed to 493 pharmacists. This questionnaire asked respondents to verify an OAM prescription with and without access to the treatment protocol and to comment on their experience and opinions.Results When using standard reference sources, the pharmacists had sufficient information to verify 7% (n = 7) of OAM prescriptions reviewed. Having access to the treatment protocol increased the number of prescriptions that could be verified to 16% (n = 16) (p = <0.01). Lack of access to body surface area and failure to communicate deliberate deviations from standard doses prevented the verification of most OAM prescriptions (n = 84). The response rate to the questionnaire was 6.4% (n = 32). Pharmacists reported that the protocols were a valuable source of information and reported they would like access to them in the future.Conclusion Facilitating access to the treatment protocol at the time of dispensing of OAM increases the number of prescriptions that can be verified and safely dispensed. However, implementing this measure alone is insufficient to address the safety concerns associated with the dispensing of OAM prescriptions by non-specialist pharmacists.ReferencesIrish Medication Safety Network. IMSN briefing document on oral anticancer medicines. 2011British Oncology Pharmacists Association (BOPA). Standards for the verification of prescriptions for cancer medicines. 2013ReferencesNo conflict of interest.